Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 28
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Amneal Pharmaceuticals Inc
AMRX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$21.34
-0.10
-0.47%
Ult. Agg.: Oct 28, 9:02 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 6 giorni da adesso in mar nov 3rd, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 6 giorni alle 8:30 AM
Clicca per vedere il webcast
Amneal Pharmaceuticals Financials
Amneal Pharmaceuticals (AMRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200
Benzinga Newsdesk
PRO
Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate
Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. This is a 20 percent increase over earnings of $0.25 per share
Benzinga Newsdesk
PRO
Amneal Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $0.95-$1.05 vs $1.00 Est; Affirms FY2026 Sales Guidance of $3.050B-$3.150B vs $3.100B Est
Benzinga Newsdesk
PRO
Amneal Pharmaceuticals Q1 Adj. EPS $0.27 Beats $0.23 Estimate, Sales $722.519M Miss $757.228M Estimate
Benzinga Newsdesk
Earnings Scheduled For May 1, 2026
Benzinga Insights
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up to $1.03 in 2026 earnings.
Vandana Singh
